FDA Approves Lyrfigtu in FGFR2 Cholangiocarcinoma
The FDA approved lirafugratinib, branded Lyrfigtu, for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement. In the single-arm REFOCUS study of 116 FGFR-inhibitor-naive patients, independently reviewed…
